News & Events

Technology Opportunity Webinar: Nestorone®/Testosterone Male Contraceptive Gel

In this free, NIH webinar hosted by TTC, attendees will learn about a first-of-its-kind male contraceptive hormonal gel, Nestorone/Testosterone (NES/T), co-developed by the NICHD and Population Council through the Contraceptive Clinical Trials Network (CCTN). This topical daily self-applied transdermal gel is designed to provide full sperm suppression within 8-12 weeks and be reversible after 12-16 weeks of ending application. This presentation will showcase NES/T gel as an innovative user-controlled option for male contraception.